Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool February 2, 2005 Alyce Lomax	CVS's Shot in the Arm Buying the Eckerd drugstore chain from J.C. Penney was apparently a good move for CVS. It continues to benefit from the purchase, reporting positive earnings and beating analysts' expectations by a penny.
The Motley Fool May 9, 2005 Timothy M. Otte	Flu Means All's Well for CVS Strong comp sales and benefits from the Eckerd acquisition drive CVS to a solid first quarter. Investors, take note.
The Motley Fool June 10, 2004 Alyce Lomax	Summer Starts at CVS The drugstore company releases same-store sales results on the cusp of its Eckerd acquisition.
BusinessWeek September 19, 2005 Gene G. Marcial	CVS' Ever-Expanding Aisles According to analysts, the aging population and improving pipeline of new drugs will help the retail pharmacy achieve its goal of 15% overall long-term earnings growth. Investors, take note.
The Motley Fool January 8, 2007 Matthew Crews	CVS' Tightrope Walk The drugstore chain's aggressive growth strategy continues to pay off -- for now. Investors, take note.
The Motley Fool November 10, 2004 Dave Marino-Nachison	Investors Adjusting to Larger CVS The drugstore company's chains have done nothing but rise since the Eckerd buy. Investors have pulled the company's shares steadily upward since the merger closed.
The Motley Fool March 9, 2005 Steven Mallas	CVS Comps Feast on Flu CVS enjoys a nice jump in same-store sales for the month of February -- thanks, in part, to colds and the flu.
The Motley Fool June 2, 2004 Alyce Lomax	Walgreen's Mellow May Will the drugstore chain get a taste of its own medicine?
The Motley Fool September 27, 2007 Ryan Fuhrmann	Rite Aid Looks a Little Peaked Bigger doesn't necessarily mean better for the drugstore retailer; it has quite a bit of work to do to convince investors it can successfully manage the empire that it has acquired.
The Motley Fool January 3, 2005 Nathan Slaughter	Walgreen Seeing Green Rivals CVS and Rite Aid have a bitter pill to swallow as Walgreen stays strong. While Walgreen's revenues were in line with forecasts, the stronger-than-expected bottom line has the stock gaining ground.
The Motley Fool April 9, 2007 Mike Cianciolo	CVS: Continued Vigorous Sales The drugstore chain grows sales and itself in March. Investors, take note.
The Motley Fool May 8, 2007 Ryan Fuhrmann	CVS/Caremark Tie the Knot While it's too early to see if CVS blazed a new health-care trail by combining a drugstore chain with giant pharmacy benefit manager Caremark, there are still interesting tidbits to pass along to investors from recently reported results.
The Motley Fool May 4, 2011 Jason Knapp	Generic Drugs and Old People Could Make You Rich CVS hasn't generated market-beating returns yet -- but it will.
The Motley Fool June 28, 2005 Mike Cianciolo	Just What Investors Prescribed With another quarter of stellar growth at Walgreen, the stock approaches its highest price ever.
The Motley Fool August 31, 2011 Shubh Datta	CVS Caremark Flattened by Higher Costs CVS Caremark profits remained relatively flat this quarter despite a substantial increase in revenue.
The Motley Fool November 2, 2006 Ryan Fuhrmann	CVS Blazes a New Healthcare Trail Strong third-quarter earnings aside, the merger announcement with pharmacy benefit manager Caremark was the real shocker here. Investors, take note.
The Motley Fool February 12, 2004 Dave Marino-Nachison	CVS Bags Big 2003 A strong year for the drugstore giant has spilled into January.
The Motley Fool February 4, 2008 Timothy M. Otte	CVS Has Major Mo' Fourth-quarter results cap a stellar year for the drugstore retailer.
The Motley Fool August 15, 2005 Bobby Shethia	Walgreen's Prescription for Success The drugstore chain's smart and steady growth makes it a good choice for investors.
The Motley Fool August 4, 2004 Phil Wohl	CVS's Prescription for Competition The national drugstore chain is looking to take advantage of increased size.
The Motley Fool June 24, 2011 Shubh Datta	A Big Question Looms for Walgreen Strong quarterly results enable the company to maintain its annual outlook, but a breakup costs dearly in the short term.
The Motley Fool November 14, 2006 Nathan Parmelee	Time to Love Wal-Mart Again Some pretty handsome returns can be earned by investors who pick up the retailer's shares on the days when there is bad news and hold patiently for a few years.
The Motley Fool September 21, 2006 Vitaliy Katsenelson	Don't Hit the Panic Button Just Yet Wall Street plays the overreacting game; Walgreen and CVS suffer. These stocks have big tailwinds behind them.
The Motley Fool March 22, 2010 Dave Mock	A Big Upgrade for CVS Caremark This bullish call comes from more than just one analyst.
The Motley Fool April 29, 2010 Brian Orelli	A Prescription to Investigate Further Let's not worry just yet about Medco's margins.
The Motley Fool April 11, 2008 Ryan Fuhrmann	Rite Aid Hasn't Fully Recovered Rite Aid needs to be nursed back to health after its acquisition of Brooks Eckerd.
The Motley Fool January 4, 2008 Timothy M. Otte	Drugstore Sales Droop in December The three major drugstore chains, Walgreen, CVS, and Rite Aid, all report soft sales for December.
The Motley Fool January 13, 2004 Alyce Lomax	CVS Fever Drug stores benefit from the flu bug, but for how much longer?
The Motley Fool June 21, 2004 Seth Jayson	Walgreen's Fine Follow-Up It's another solid quarter for America's soon-to-be No. 2 drugstore.
The Motley Fool January 3, 2006 Stephen D. Simpson	Walgreen Reaps Rewards of Rx The nation's top pharmacy keeps on rolling, but investors might want to keep an eye on the new ventures.
The Motley Fool November 11, 2004 Nathan Slaughter	Children's Place Pleases The retailer reports a 52% increase in earnings ahead of its Disney Stores acquisition.
The Motley Fool March 28, 2005 Alyce Lomax	A Cool Quarter for Walgreen Are second-quarter earnings putting a damper on Walgreen?
The Motley Fool July 5, 2005 Alyce Lomax	Business As Usual at Walgreen Walgreen's same-store sales for June certainly don't disappoint. Investors might question whether the retail pharmacy can keep up the great work.
The Motley Fool May 5, 2004 Mike Cianciolo	CVS Prescribes Growth The soon-to-be leader of the drugstore market had a spectacular first quarter as a result of improved sales and margins, and CVS doesn't appear to be showing any signs of slowing down either, as the company continues to expand its business in both traditional and creative ways.
The Motley Fool September 14, 2006 Ryan Fuhrmann	Playing Defense With the Drugstore Industry Retail pharmacy August sales trends help investors discern the leader in this appealing sector.
The Motley Fool March 22, 2004 Alyce Lomax	Walgreen's Green Quarter Investors take an earnings miss to heart. But the future looks good.
The Motley Fool August 1, 2006 Selena Maranjian	Prescription for Prescription Bargains Did you know that your medications might be cheaper around the corner? Another way to offset your net expenses on medications is to make some money on drugs -- by investing in drug-related firms.
The Motley Fool April 8, 2004 Seth Jayson	Rite Aid Wrings Out Profits Net store closings and comps increases bring black ink to the pharmacy's bottom line.
The Motley Fool July 6, 2004 Alyce Lomax	Not Ready for Rite Aid Can the drugstore chain hold a candle to the competition? Its shares are trading at 22 times forward earnings, making it a seemingly less-than-advantageous time to place a bet on them.
The Motley Fool February 3, 2006 Nathan Parmelee	CVS Looks Healthy The drugstore chain handles acquisitions without faltering -- this stock may be worth considering.
The Motley Fool December 8, 2004 Nathan Slaughter	What's Wrong at Rite-Aid? Rite-Aid steers guidance lower after a difficult November.
The Motley Fool June 25, 2007 Ryan Fuhrmann	Foolish Forecast: Rite Aid Aims for Healthy Growth The drugstore operator is set to report its first-quarter earnings. Investors, here is what you can expect to see.
The Motley Fool December 11, 2006 Matthew Crews	Rite Aid: Comps Mean Competition The pharmacy chain reported positive same-store results for November. Investors, take note.
The Motley Fool November 9, 2005 Steven Mallas	CVS Needs Rx for Cash The drugstore chain has the prescription for earnings growth, but investors need to keep an eye on free cash flow.
The Motley Fool November 5, 2007 Timothy M. Otte	CVS Is in the Zone Pharmacy giant CVS grew EPS by 36% in the third quarter. The company has been on a roll since its merger with Caremark last year.
BusinessWeek April 9, 2007 Gene G. Marcial	Hail To CVS/Caremark Deal or no deal, CVS was already a fave on Wall Street. And now that it has acquired Caremark Rx, No.2 in pharmacy-benefits management, Goldman Sachs, UBS, and Matrix USA are even more bullish.
The Motley Fool May 2, 2008 Timothy M. Otte	CVS Caremark and the Snickers Factor The soft economy has hit some retail sectors hard. But there are still pockets of life, and CVS Caremark is one of the companies leading the way.
The Motley Fool June 11, 2007 Mike Cianciolo	Rite Aid's Generic Sales The drugstore chain gradually increases sales, and catches up to the big boys in one way. Investors, take note.
The Motley Fool April 7, 2010 Brian Orelli	Teva: Hold Until Things Turn Ugly Despite the drugmaker's recent success, its future looks precarious.
The Motley Fool September 21, 2006 Nathan Parmelee	Wal-Mart Goes Generic The supposed most terrible retailer of all is doing a very good thing with generic drug sales. The program will, of course, benefit Wal-Mart by creating additional traffic to its stores. This move could change the game for a number of retailers over the next few years.